{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:04:52Z","timestamp":1790139892235,"version":"4.0.1"},"reference-count":162,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The occurrence of bone metastasis is a grave medical concern that substantially impacts the quality of life in patients with cancer. The precise mechanisms underlying bone metastasis remain unclear despite extensive research efforts, and efficacious therapeutic interventions are currently lacking. The ability of osteoclasts to degrade the bone matrix makes them a crucial factor in the development of bone metastasis. Osteoclasts are implicated in several aspects of bone metastasis, encompassing the formation of premetastatic microenvironment, suppression of the immune system, and reactivation of quiescent tumor cells. Contemporary clinical interventions targeting osteoclasts have proven effective in mitigating bone-related symptoms in patients with cancer. This review comprehensively analyzes the mechanistic involvement of osteoclasts in bone metastasis, delineates potential therapeutic targets associated with osteoclasts, and explores clinical evidence regarding interventions targeting osteoclasts.<\/jats:p>","DOI":"10.3389\/fonc.2024.1445025","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T05:20:26Z","timestamp":1722489626000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["The emerging role of osteoclasts in the treatment of bone metastases: rationale and recent clinical evidence"],"prefix":"10.3389","volume":"14","author":[{"given":"Youjun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanshi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115783","article-title":"Epidemiology of bone metastases","volume":"158","author":"Ryan","year":"2022","journal-title":"Bone"},{"key":"B2","article-title":"Monitoring of bone metastases","volume":"111","author":"Galasko","year":"1981","journal-title":"Schweiz Med Wochenschr"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41580-020-00279-w","article-title":"Mechanisms of bone development and repair","volume":"21","author":"Salhotra","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1152\/PHYSREV.00012.2019","article-title":"Bone metastasis: mechanisms, therapies, and biomarkers","volume":"101","author":"Cl\u00e9zardin","year":"2021","journal-title":"Physiol Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Prim"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7326\/M22-1034","article-title":"Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: A living clinical guideline from the american college of physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann Intern Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013020.pub2","article-title":"Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis","volume":"12","author":"Jakob","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2019.02.004","article-title":"Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: A systematic review and network meta-analysis","volume":"137","author":"Tesfamariam","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/J.TRECAN.2018.12.004","article-title":"Bone metastasis: Find your niche and fit in","volume":"5","author":"Zhang","year":"2019","journal-title":"Trends Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10070218","article-title":"The osteoclast in bone metastasis: Player and target","volume":"10","author":"Maurizi","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","article-title":"Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody","volume":"76","author":"von Moos","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/JNCI\/DJZ215","article-title":"Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307","volume":"112","author":"Gralow","year":"2020","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/S41232-022-00213-X","article-title":"Osteoclast biology in the single-cell era","volume":"42","author":"Tsukasaki","year":"2022","journal-title":"Inflamm Regen"},{"key":"B17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-020-0165-3","article-title":"Targeting the premetastatic niche: epigenetic therapies in the spotlight","volume":"5","author":"Low","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.09.006","article-title":"Emerging players in prostate cancer-bone niche communication","volume":"7","author":"Furesi","year":"2021","journal-title":"Trends Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/J.MOLMED.2014.06.001","article-title":"Osteoclasts: more than \u2018bone eaters\u2019","volume":"20","author":"Charles","year":"2014","journal-title":"Trends Mol Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41413-018-0019-6","article-title":"Paracrine and endocrine actions of bone-the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts","volume":"6","author":"Han","year":"2018","journal-title":"Bone Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7150\/THNO.45351","article-title":"Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells","volume":"11","author":"Yuan","year":"2021","journal-title":"Theranostics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e144579","DOI":"10.1172\/JCI144579","article-title":"RSPO2 and RANKL signal through LGR4 to regulate osteoclastic premetastatic niche formation and bone metastasis","volume":"132","author":"Yue","year":"2022","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ADVS.202001961","article-title":"RNF219\/ \u03b1-Catenin\/LGALS3 axis promotes hepatocellular carcinoma bone metastasis and associated skeletal complications","volume":"8","author":"Zhang","year":"2020","journal-title":"Adv Sci (Weinheim Baden-Wurttemberg Ger"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12056","article-title":"Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1-targeting miRNA-92a-1-5p","volume":"10","author":"Yu","year":"2021","journal-title":"J Extracell vesicles"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/SREP40487","article-title":"Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/S10020-021-00282-7","article-title":"miR-325-3p, a novel regulator of osteoclastogenesis in osteolysis of colorectal cancer through targeting S100A4","volume":"27","author":"Chengling","year":"2021","journal-title":"Mol Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/J.CANLET.2021.11.017","article-title":"Tumor-derived miR-378a-3p-containing extracellular vesicles promote osteolysis by activating the Dyrk1a\/Nfatc1\/Angptl2 axis for bone metastasis","volume":"526","author":"Wang","year":"2022","journal-title":"Cancer Lett"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/JEV2.12068","article-title":"Small extracellular vesicles deliver osteolytic effectors and mediate cancer-induced osteolysis in bone metastatic niche","volume":"10","author":"Ma","year":"2021","journal-title":"J Extracell vesicles"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27010211","article-title":"The emerging role of MicroRNAs in bone diseases and their therapeutic potential","volume":"27","author":"Bravo V\u00e1zquez","year":"2021","journal-title":"Molecules"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2015.04.015","article-title":"MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment","volume":"97","author":"Kaboli","year":"2015","journal-title":"Pharmacol Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/JEV2.12042","article-title":"Prostate cancer extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol-dependent manner","volume":"10","author":"Henrich","year":"2020","journal-title":"J Extracell vesicles"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCELL.2017.07.001","article-title":"Intravascular survival and extravasation of tumor cells","volume":"32","author":"Strilic","year":"2017","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-031521-040919","article-title":"Osteoclasts, master sculptors of bone","volume":"18","author":"Veis","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26896","article-title":"Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer","volume":"234","author":"Safarzadeh","year":"2019","journal-title":"J Cell Physiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00172","article-title":"MDSCs: Key criminals of tumor pre-metastatic niche formation","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1019864","article-title":"Contribution of immune cells to bone metastasis pathogenesis","volume":"13","author":"He","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.664871","article-title":"The macrophage-osteoclast axis in osteoimmunity and osteo-related diseases","volume":"12","author":"Yao","year":"2021","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115755","article-title":"Dendritic cells development into osteoclast-type APCs by 4T1 breast tumor t cells milieu boost bone consumption","volume":"143","author":"Monteiro","year":"2021","journal-title":"Bone"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2017.00297","article-title":"Novel strategy to expand super-charged NK cells with significant potential to lyse and differentiate cancer stem cells: Differences in NK expansion and function between healthy and cancer patients","volume":"8","author":"Kaur","year":"2017","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"20363","DOI":"10.1038\/S41598-020-76702-1","article-title":"Osteoclast-expanded super-charged NK-cells preferentially select and expand CD8+ t cells","volume":"10","author":"Kaur","year":"2020","journal-title":"Sci Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1182\/BLOOD-2016-03-707547","article-title":"Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22411","article-title":"T cell suppression by osteoclasts in vitro","volume":"226","author":"Grassi","year":"2011","journal-title":"J Cell Physiol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4615","article-title":"Bone microenvironment-suppressed t cells increase osteoclast formation and osteolytic bone metastases in mice","volume":"37","author":"Arellano","year":"2022","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202107787","article-title":"Siglec15 checkpoint blockade for simultaneous immunochemotherapy and osteolysis inhibition in lung adenocarcinoma spinal metastasis via a hollow nanoplatform","volume":"18","author":"Liang","year":"2022","journal-title":"Small"},{"key":"B45","doi-asserted-by":"publisher","first-page":"281","DOI":"10.21037\/atm-22-764","article-title":"Siglec15 facilitates the progression of non-small cell lung cancer and is correlated with spinal metastasis","volume":"10","author":"Liang","year":"2022","journal-title":"Ann Transl Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/JBMR.2868","article-title":"Inflammatory osteoclasts prime TNF\u03b1-producing CD4+ t cells and express CX3 CR1","volume":"31","author":"Ib\u00e1\u00f1ez","year":"2016","journal-title":"J Bone Miner Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/ELIFE.54493","article-title":"Dissecting the phenotypic and functional heterogeneity of mouse inflammatory osteoclasts by the expression of Cx3cr1","volume":"9","author":"Madel","year":"2020","journal-title":"Elife"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0038199","article-title":"Osteoclast activated FoxP3+ CD8+ t-cells suppress bone resorption in vitro","volume":"7","author":"Buchwald","year":"2012","journal-title":"PloS One"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0305","article-title":"Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis","volume":"73","author":"Sawant","year":"2013","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0232","article-title":"Effective treatment of established bone metastases can be achieved by combinatorial osteoclast blockade and depletion of granulocytic subsets","volume":"9","author":"Capietto","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-03966-9","article-title":"Beyond immunosuppressive effects: dual roles of myeloid-derived suppressor cells in bone-related diseases","volume":"78","author":"Ling","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/BLOOD-2009-11-255026","article-title":"Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ t cells","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101855","article-title":"Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells","volume":"189","author":"Sawant","year":"2012","journal-title":"J Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/J.SEMCANCER.2021.05.007","article-title":"Thorny ground, rocky soil: Tissue-specific mechanisms of tumor dormancy and relapse","volume":"78","author":"Lim","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/S41568-020-0263-0","article-title":"The dormant cancer cell life cycle","volume":"20","author":"Phan","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2020.567844","article-title":"Osteocytes and bone metastasis","volume":"11","author":"Riquelme","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/J.CCELL.2014.11.017","article-title":"The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells","volume":"27","author":"Wang","year":"2015","journal-title":"Cancer Cell"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/CANCERS13061366","article-title":"Osteoblast-derived paracrine and juxtacrine signals protect disseminated breast cancer cells from stress","volume":"13","author":"Hughes","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/BLOOD.2018880930","article-title":"A niche-dependent myeloid transcriptome signature defines dormant myeloma cells","volume":"134","author":"Khoo","year":"2019","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1051","article-title":"Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGF\u03b2RIII-p38MAPK-pS249\/T252RB pathway","volume":"78","author":"Yu-Lee","year":"2018","journal-title":"Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1038\/NCOMMS9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat Commun"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1084\/JEM.20180661","article-title":"Wnt5a induces and maintains prostate cancer cells dormancy in bone","volume":"216","author":"Ren","year":"2019","journal-title":"J Exp Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/S41416-019-0501-Y","article-title":"Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry","volume":"121","author":"Capulli","year":"2019","journal-title":"Br J Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCR.2011.11.002","article-title":"VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging \u03b14\u03b21-positive osteoclast progenitors","volume":"20","author":"Lu","year":"2011","journal-title":"Cancer Cell"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/JBMR.3618","article-title":"Understanding the bone in cancer metastasis","volume":"33","author":"Fornetti","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBRC.2010.03.063","article-title":"Long bone osteoclasts display an augmented osteoclast phenotype compared to calvarial osteoclasts","volume":"394","author":"Zenger","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/J.BONE.2013.08.007","article-title":"Jaw bone marrow-derived osteoclast precursors internalize more bisphosphonate than long-bone marrow precursors","volume":"57","author":"Vermeer","year":"2013","journal-title":"Bone"},{"key":"B68","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/J.BONE.2016.02.010","article-title":"Osteoblasts of calvaria induce higher numbers of osteoclasts than osteoblasts from long bone","volume":"86","author":"Wan","year":"2016","journal-title":"Bone"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140214","article-title":"Bone marrow adipogenic lineage precursors promote osteoclastogenesis in bone remodeling and pathologic bone loss","volume":"131","author":"Yu","year":"2021","journal-title":"J Clin Invest"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IJMS21113774","article-title":"Increase in the number of bone marrow osteoclast precursors at different skeletal sites, particularly in long bone and jaw marrow in mice lacking IL-1RA","volume":"21","author":"Ascone","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/S41413-022-00206-Z","article-title":"Specific inflammatory osteoclast precursors induced during chronic inflammation give rise to highly active osteoclasts associated with inflammatory bone loss","volume":"10","author":"Meirow","year":"2022","journal-title":"Bone Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0b013e3283504528","article-title":"Study on the distribution features of bone metastases in prostate cancer","volume":"33","author":"Wang","year":"2012","journal-title":"Nucl Med Commun"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100219","article-title":"Bone metastasis pattern of cancer patients with bone metastasis but no visceral metastasis","volume":"15","author":"Zhu","year":"2019","journal-title":"J Bone Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1186\/S41232-019-0111-3","article-title":"RANKL biology: bone metabolism, the immune system, and beyond","volume":"40","author":"Ono","year":"2020","journal-title":"Inflamm Regen"},{"key":"B75","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/J.MOLMED.2005.11.007","article-title":"RANKL-RANK signaling in osteoclastogenesis and bone disease","volume":"12","author":"Wada","year":"2006","journal-title":"Trends Mol Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/S42255-019-0104-1","article-title":"Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone","volume":"1","author":"Asano","year":"2019","journal-title":"Nat Metab"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/IJC.29439","article-title":"OPG-fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone","volume":"137","author":"Ottewell","year":"2015","journal-title":"Int J Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2022.824117","article-title":"Roles of the RANKL-RANK axis in immunity-implications for pathogenesis and treatment of bone metastasis","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1172\/JCI133334","article-title":"PD-1 blockade inhibits osteoclast formation and murine bone cancer pain","volume":"130","author":"Wang","year":"2020","journal-title":"J Clin Invest"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/345442A0","article-title":"The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene","volume":"345","author":"Yoshida","year":"1990","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/S12276-020-0484-Z","article-title":"The m-CSF receptor in osteoclasts and beyond","volume":"52","author":"Mun","year":"2020","journal-title":"Exp Mol Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1210\/EN.2006-0547","article-title":"Colony-stimulating factor-1 increases osteoclast intracellular pH and promotes survival via the electroneutral Na\/HCO3 cotransporter NBCn1","volume":"148","author":"Bouyer","year":"2007","journal-title":"Endocrinology"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/J.BONE.2014.06.017","article-title":"CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems","volume":"66","author":"Liverani","year":"2014","journal-title":"Bone"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/LABINVEST.2014.1","article-title":"Colony-stimulating factor 1 potentiates lung cancer bone metastasis","volume":"94","author":"Hung","year":"2014","journal-title":"Lab Invest"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates t-cell infiltration in the sarcoma microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/J.0105-2896.2005.00335.X","article-title":"The role(s) of src kinase and cbl proteins in the regulation of osteoclast differentiation and function","volume":"208","author":"Horne","year":"2005","journal-title":"Immunol Rev"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/J.JBC.2021.100790","article-title":"Characterization of unique functionalities in c-src domains required for osteoclast podosome belt formation","volume":"296","author":"Matsubara","year":"2021","journal-title":"J Biol Chem"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2021.111822","article-title":"The nonreceptor protein tyrosine kinase src participates in every step of cancer-induced bone pain","volume":"141","author":"Li","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/S00404-020-05496-4","article-title":"Dasatinib prevents skeletal metastasis of osteotropic MDA-MB-231 cells in a xenograft mouse model","volume":"301","author":"Heilmann","year":"2020","journal-title":"Arch Gynecol Obstet"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.AAI9338","article-title":"RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis","volume":"9","author":"Andrade","year":"2017","journal-title":"Sci Transl Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.7150\/THNO.54235","article-title":"Vertebral-specific activation of the CX3CL1\/ICAM-1 signaling network mediates non-small-cell lung cancer spinal metastasis by engaging tumor cell-vertebral bone marrow endothelial cell interactions","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"B92","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/S12943-016-0552-0","article-title":"Pharmacological targeting of CXCL12\/CXCR4 signaling in prostate cancer bone metastasis","volume":"15","author":"Conley-LaComb","year":"2016","journal-title":"Mol Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"7103","DOI":"10.1158\/0008-5472.CAN-14-0612","article-title":"CCR5 receptor antagonists block metastasis to bone of v-src-oncogene-transformed metastatic prostate cancer cell lines","volume":"74","author":"Sicoli","year":"2014","journal-title":"Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/S13402-019-00491-7","article-title":"Mechanism of lung adenocarcinoma spine metastasis induced by CXCL17","volume":"43","author":"Liu","year":"2020","journal-title":"Cell Oncol (Dordr)"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/S00432-019-02950-Y","article-title":"Targeting cathepsin k diminishes prostate cancer establishment and growth in murine bone","volume":"145","author":"Liang","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1021\/ACS.BIOCONJCHEM.1C00036","article-title":"Design and synthesis of cathepsin-K-Activated osteoadsorptive fluorogenic sentinel (OFS) probes for detecting early osteoclastic bone resorption in a multiple myeloma mouse model","volume":"32","author":"Richard","year":"2021","journal-title":"Bioconjug Chem"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/S41388-019-0774-X","article-title":"Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer","volume":"38","author":"Sinha","year":"2019","journal-title":"Oncogene"},{"key":"B98","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.3390\/CURRONCOL29080471","article-title":"Cathepsin k: A versatile potential biomarker and therapeutic target for various cancers","volume":"29","author":"Qian","year":"2022","journal-title":"Curr Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.2174\/1874467214666210211162118","article-title":"Inhibitory effects of cathepsin k inhibitor (ODN-MK-0822) on the paracrine pro-osteoclast factors of breast cancer cells","volume":"14","author":"Vashum","year":"2021","journal-title":"Curr Mol Pharmacol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/S41418-019-0312-Y","article-title":"Gut microbiota-stimulated cathepsin k secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer","volume":"26","author":"Li","year":"2019","journal-title":"Cell Death Differ"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/S41413-017-0004-5","article-title":"mTOR signaling in skeletal development and disease","volume":"6","author":"Chen","year":"2018","journal-title":"Bone Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2017.00054","article-title":"Regulation of osteoclast growth and fusion by mTOR\/raptor and mTOR\/rictor\/Akt","volume":"5","author":"Tiedemann","year":"2017","journal-title":"Front Cell Dev Biol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00684","article-title":"mTORC1 activation in osteoclasts prevents bone loss in a mouse model of osteoporosis","volume":"10","author":"Hiraiwa","year":"2019","journal-title":"Front Pharmacol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3172","article-title":"mTORC1 inhibits NF-\u03baB\/NFATc1 signaling and prevents osteoclast precursor differentiation, In vitro and in mice","volume":"32","author":"Zhang","year":"2017","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2799-0","article-title":"Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin","volume":"143","author":"Abdelaziz","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2011.09.026","article-title":"Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases","volume":"314","author":"Hussein","year":"2012","journal-title":"Cancer Lett"},{"key":"B107","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ceb.2022.01.001","article-title":"Plasmalemmal interface for calcium signaling in osteoclast differentiation","volume":"74","author":"Okada","year":"2022","journal-title":"Curr Opin Cell Biol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/J.PBIOMOLBIO.2022.10.006","article-title":"Siglec-15 as multifunctional molecule involved in osteoclast differentiation, cancer immunity and microbial infection","author":"Huang","year":"2022","journal-title":"Prog Biophys Mol Biol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/S41413-021-00161-1","article-title":"An antibody against siglec-15 promotes bone formation and fracture healing by increasing TRAP+ mononuclear cells and PDGF-BB secretion","volume":"9","author":"Zhen","year":"2021","journal-title":"Bone Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2020.104728","article-title":"The diverse functions of siglec-15 in bone remodeling and antitumor responses","volume":"155","author":"Kang","year":"2020","journal-title":"Pharmacol Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41413-022-00186-0","article-title":"Sialylation of TLR2 initiates osteoclast fusion","volume":"10","author":"Dou","year":"2022","journal-title":"Bone Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101165","article-title":"Osteoclast-derived apoptotic bodies inhibit naive CD8(+) t cell activation via Siglec15, promoting breast cancer secondary metastasis","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0374-x","article-title":"Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1073932","article-title":"Prognostic value of siglec-15 expression in patients with solid tumors: A meta-analysis","volume":"12","author":"Jiang","year":"2022","journal-title":"Front Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi162","article-title":"Bisphosphonates in breast cancer","volume":"16","author":"Coleman","year":"2005","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/JCB.25266","article-title":"Risks and benefits of bisphosphonate therapies","volume":"117","author":"Reyes","year":"2016","journal-title":"J Cell Biochem"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1093\/JNCI\/DJG038","article-title":"A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B118","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1093\/ANNONC\/MDN429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow\u2013a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4997","article-title":"Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer","volume":"26","author":"Saarto","year":"2008","journal-title":"J Clin Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial","volume":"19","author":"Saarto","year":"2001","journal-title":"J Clin Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1093\/JNCI\/DJK178","article-title":"Oral sodium clodronate for nonmetastatic prostate cancer\u2013results of a randomized double-blind placebo-controlled trial: Medical research council PR04 (ISRCTN61384873)","volume":"99","author":"Mason","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1007\/S10147-016-1037-2","article-title":"A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial","volume":"22","author":"Kamba","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJCA.2018.02.004","article-title":"Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01\/04) study","volume":"94","author":"Wilson","year":"2018","journal-title":"Eur J Cancer"},{"key":"B124","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.21.02647","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update","volume":"40","author":"Eisen","year":"2022","journal-title":"J Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/S00520-021-06714-8","article-title":"Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers","volume":"30","author":"Alzahrani","year":"2022","journal-title":"Support Care Cancer"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2018.10.004","article-title":"Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management","volume":"15","author":"D\u2019Oronzo","year":"2019","journal-title":"J Bone Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03148","article-title":"Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a cancer care ontario guideline","volume":"38","author":"Saylor","year":"2020","journal-title":"J Clin Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/J.EURURO.2014.02.014","article-title":"Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the zometa european study (ZEUS)","volume":"67","author":"Wirth","year":"2015","journal-title":"Eur Urol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/J.EURURO.2012.05.007","article-title":"Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid","volume":"65","author":"Saad","year":"2014","journal-title":"Eur Urol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National surgical adjuvant breast and bowel project protocol b-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials","volume":"386","author":"Coleman","year":"2015","journal-title":"Lancet"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.2167","article-title":"German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer","volume":"31","author":"Von Minckwitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00311","article-title":"Daily oral ibandronate with adjuvant endocrine therapy in postmenopausal women with estrogen receptor-positive breast cancer (BOOG 2006-04): Randomized phase III TEAM-IIB trial","volume":"40","author":"Vliek","year":"2022","journal-title":"J Clin Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30603-4","article-title":"Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01\/04) trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1002\/art.40874","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: Final results of a twenty-Four-Month randomized, double-blind, double-dummy trial","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1007\/S00198-019-05233-X","article-title":"Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates","volume":"31","author":"Miller","year":"2020","journal-title":"Osteoporos Int"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.6716","article-title":"Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7437","article-title":"Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 (Alliance)","volume":"35","author":"Shapiro","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/NRCLINONC.2011.197","article-title":"Denosumab in patients with cancer-a surgical strike against the osteoclast","volume":"9","author":"Brown","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet (London England)"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/J.JTHO.2020.06.011","article-title":"A randomized open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The european thoracic oncology platform (ETOP) and european organisation for research and treatment of cancer (EORTC) SPLENDOU","volume":"15","author":"Peters","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/J.EJCA.2015.09.011","article-title":"Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics","volume":"53","author":"Lipton","year":"2016","journal-title":"Eur J Cancer"},{"key":"B146","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/S11914-019-00502-4","article-title":"Stopping denosumab","volume":"17","author":"Lamy","year":"2019","journal-title":"Curr Osteoporos Rep"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.090830","article-title":"Effects of the src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase i trial","volume":"25","author":"Hannon","year":"2010","journal-title":"J Bone Miner Res"},{"key":"B148","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/J.PHRS.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1691","article-title":"Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Yu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(13)70479-0","article-title":"Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial","volume":"14","author":"Araujo","year":"2013","journal-title":"Lancet Oncol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10549-016-3911-z","article-title":"Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622","volume":"159","author":"Schott","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr261","article-title":"Phase II study of single-agent bosutinib, a Src\/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy","volume":"23","author":"Campone","year":"2012","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2079-z","article-title":"A phase 2 study of KX2-391, an oral inhibitor of src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer","volume":"71","author":"Antonarakis","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/S10549-023-06873-8","article-title":"Aromatase inhibition plus\/minus src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study","volume":"199","author":"Oswald","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00433","article-title":"Cathepsin k: The action in and beyond bone","volume":"8","author":"Dai","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2010.N.059","article-title":"The cathepsin k inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial","volume":"10","author":"Jensen","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"B157","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S2213-8587(19)30346-8","article-title":"Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT extension study","volume":"7","author":"McClung","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1186\/S12885-015-1717-8","article-title":"Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells","volume":"15","author":"Simone","year":"2015","journal-title":"BMC Cancer"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1093\/JNCI\/DJT026","article-title":"Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2","volume":"105","author":"Gnant","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1007\/S00432-013-1518-X","article-title":"Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study","volume":"139","author":"Maass","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113936","article-title":"De novo steroidogenesis in tumor cells drives bone metastasis and osteoclastogenesis","volume":"43","author":"Sandor","year":"2024","journal-title":"Cell Rep"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCONREL.2021.11.005","article-title":"Targeting bone microenvironments for treatment and early detection of cancer bone metastatic niches","volume":"341","author":"Yang","year":"2022","journal-title":"J Control Release"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1445025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T05:20:30Z","timestamp":1722489630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1445025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":162,"alternative-id":["10.3389\/fonc.2024.1445025"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1445025","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"article-number":"1445025"}}